Please login to the form below

Not currently logged in
Email:
Password:

Cabometyx

This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Data presented at the 2020 European Society for Medical Oncology (ESMO) virtual congress detailed a 40% reduction in the risk of death among previously untreated RCC patients receiving Opdivo plus Cabometyx ... The combination also met the primary trial

Latest news

More from news
Approximately 6 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics